Polumiros Inc.’s lead product is ReFilx™, a soft tissue filler for the permanent restoration of breast tissue defects in breast cancer patients post lumpectomy. This product will not only improve the quality of life and survivorship for breast cancer patients but also has a great potential to improve oncological outcomes. Please join us in this venture as we bring ReFilx™ to market and improve patient lives.
Sector: Implanted Medical Devices
Product: ReFilx, a soft tissue filler for the permanent restoration of breast tissue defects.
Market Size: $3.3 Billion by 2019
Development Stage: Pre-Clinical Testing
Funds Raised: $0.28 Million in non-dilutive funding
Funding: Seeking $1.5 Million in seed funding